Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 677Neoplasms 593Colorectal Neoplasms 292Carcinoma, Non-Small-Cell Lung 292Prostatic Neoplasms 281Lung Neoplasms 223Melanoma 161Multiple Myeloma 150Neoplasm Metastasis 146Head and Neck Neoplasms 143Pancreatic Neoplasms 141Ovarian Neoplasms 133Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 123Colonic Neoplasms 112Brain Neoplasms 112Squamous Cell Carcinoma of Head and Neck 111Uterine Cervical Neoplasms 108Stomach Neoplasms 105Recurrence 101Lymphoma 101Glioblastoma 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 82Lymphoma, Non-Hodgkin 82Hematologic Neoplasms 80Urinary Bladder Neoplasms 78Lymphoma, Follicular 78Glioma 75Parkinson Disease 4, Autosomal Dominant Lewy Body 74Leukemia, Lymphocytic, Chronic, B-Cell 72

Interventions

Sodium Chloride 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Severe Acute Respiratory Syndrome × 1 year × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡